Navigation Links
Medbox Executes $6 Million Equity Transaction with Private Investment Firm
Date:2/19/2013

HOLLYWOOD, Calif., Feb. 19, 2013 /PRNewswire/ -- Medbox, Inc. (OTC Markets: MDBX) (www.medboxinc.com), announced that the company has executed a $6 million equity transaction with a private investment firm involving a restricted stock purchase directly from the company at market rate as of January 17, 2013 for $5 million and the remaining $1 million stock purchase at a discount to market. The shares issued are considered a long-term investment for the firm that specializes in funding up-and-coming companies. The investment firm has made an initial payment to Medbox and is scheduled to complete funding of the transaction by May 2013.  

The instant transaction, along with other opportunities currently being investigated by Medbox management, provides alternative acquisition funding sources in lieu of the company's founder selling affiliate shares into the market in order to fund expansion. To date, the company reports that the founder has not liquidated any shares into the public market. In addition, based on advice from counsel, affiliate shares cannot be sold publicly for 90 days after the company files its Form 10 with the SEC to become fully reporting. With the Form 10 on pace to being filed next month, the company has decided to seek out more traditional funding sources in lieu of founder funded expansion.

"Although we have an aggressive acquisition schedule for this year, the $6 million equity transaction, other viable transactions that have been presented to the company, and the company's earnings, will allow us the capital we need to go after any viable acquisitions as well as explore opportunities within our company to boost revenues in our existing market segments," stated Dr. Bruce Bedrick , CEO of Medbox.  

The company also announced that it is on pace to have its best financial performance quarter in company history in Q1 2013 and is in the process of closing 4 acquisition targets within Q2 2013 that have executed term sheets with Medbox.

About Medbox, Inc: 

Medbox is a leader in the development, sales and service of automated, biometrically controlled dispensing and storage systems for medicine and merchandise. Medbox has offices throughout the world, including New York, Arizona, Connecticut, Massachusetts, Tokyo, London and Toronto, and has their corporate headquarters in Los Angeles.

Medbox provides their patented systems, software and consulting services to pharmacies, dispensaries, urgent care centers, drug rehab clinics, hospitals, prison systems, hospice facilities, and medical groups worldwide.

Medbox, Inc. is a publicly traded company, and is quoted on the OTC Markets, ticker symbol MDBX.

For more information on Medbox, please contact the Medbox Investor Relations Department at (800) 762-1452 or go online to www.medboxinc.com.


'/>"/>
SOURCE Medbox, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Medbox Partners with Bio-Tech Medical Software to Create Nations Safest Prescription Drug and Medical Marijuana Distribution System
2. Medbox, Inc. Comments on Record Trading Day
3. Medbox, Inc. Featured in Multiple Media Stories in Massachusetts and California
4. Medbox, Inc. Releases Demo Video and Collateral Media Concerning How Their Systems Will Be Used in Massachusetts Medical Marijuana Dispensaries
5. Medbox Communicates with Shareholders, Comments on Pending Transition to OTC Bulletin Board, and Announces Appearance on Fox Business News Channel
6. AVT Develops Biometrically Secure Medicine Storage and Retrieval System for Medbox RX
7. Medbox, Inc. Releases 2nd Quarter Financials
8. Medbox Safe Storage and Access Lockers Gaining Popularity
9. Medbox Developing a Patent Pending Wall-Mounted Biometric Kiosk for Storage of Sensitive Medicine Samples and Supplies for Doctors Offices.
10. Medbox, Inc. Announces Top-Tier Rating by Dun & Bradstreet Credibility Corporation
11. RayBiotech, Inc. Executes Neuroscience Biomarker Master Services Agreement with Banner Sun Health Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2017)... A new independent identity strategy consultancy firm announces its ... to fill a critical niche in technical and policy ... Mark Crego and Janice Kephart together ... that span federal governments, the 9/11 Commission, private industry, ... has a common theme born from a shared passion ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... Feb. 17, 2017  If only one in ... a mutation-conferring resistance to chemotherapy, thousands of cancer ... has focused on finding these mutations in ever-smaller ... circulating tumor DNA in blood — to guide ... Unfortunately, however, detecting these genetic anomalies ...
(Date:2/16/2017)...  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing ... treatment for triple negative breast cancer (TNBC), announced today their ... program. The YEi Start in ... entrepreneurs grow their business in France ... selected to complete an intensive one week immersion in ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
Breaking Biology Technology: